CN118829645A - 新型澳瑞他汀类似物及其免疫偶联物 - Google Patents

新型澳瑞他汀类似物及其免疫偶联物 Download PDF

Info

Publication number
CN118829645A
CN118829645A CN202280092301.4A CN202280092301A CN118829645A CN 118829645 A CN118829645 A CN 118829645A CN 202280092301 A CN202280092301 A CN 202280092301A CN 118829645 A CN118829645 A CN 118829645A
Authority
CN
China
Prior art keywords
compound
structural formula
immunoconjugate
alkyl
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280092301.4A
Other languages
English (en)
Chinese (zh)
Inventor
理查·H·李
李东骏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adson Tex Treatment Co ltd
Original Assignee
Adson Tex Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adson Tex Treatment Co ltd filed Critical Adson Tex Treatment Co ltd
Publication of CN118829645A publication Critical patent/CN118829645A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202280092301.4A 2021-12-23 2022-12-21 新型澳瑞他汀类似物及其免疫偶联物 Pending CN118829645A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163293583P 2021-12-23 2021-12-23
US63/293,583 2021-12-23
PCT/US2022/053738 WO2023122228A1 (en) 2021-12-23 2022-12-21 Novel auristatin analogs and immunoconjugates thereof

Publications (1)

Publication Number Publication Date
CN118829645A true CN118829645A (zh) 2024-10-22

Family

ID=86903604

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280092301.4A Pending CN118829645A (zh) 2021-12-23 2022-12-21 新型澳瑞他汀类似物及其免疫偶联物

Country Status (10)

Country Link
US (1) US20250049937A1 (https=)
EP (1) EP4453000A4 (https=)
JP (1) JP2025500404A (https=)
KR (1) KR20240152826A (https=)
CN (1) CN118829645A (https=)
AU (1) AU2022422015A1 (https=)
CA (1) CA3241878A1 (https=)
IL (1) IL313784A (https=)
TW (1) TW202328162A (https=)
WO (1) WO2023122228A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067221A1 (zh) * 2023-09-26 2025-04-03 上海齐鲁制药研究中心有限公司 奥瑞他汀衍生物及其抗体药物偶联物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017552A1 (en) * 2013-08-01 2015-02-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
CA2951368A1 (en) * 2014-06-13 2015-12-17 Novartis Ag Auristatin derivatives and conjugates thereof
CA3205824A1 (en) * 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
US20190194315A1 (en) * 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
CN119241554A (zh) * 2017-12-15 2025-01-03 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途

Also Published As

Publication number Publication date
IL313784A (en) 2024-08-01
TW202328162A (zh) 2023-07-16
JP2025500404A (ja) 2025-01-09
WO2023122228A1 (en) 2023-06-29
US20250049937A1 (en) 2025-02-13
KR20240152826A (ko) 2024-10-22
EP4453000A4 (en) 2025-12-24
EP4453000A1 (en) 2024-10-30
AU2022422015A1 (en) 2024-07-04
CA3241878A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
JP7561141B2 (ja) カンプトテシン誘導体
JP6581630B2 (ja) 新規ベンゾジアゼピン誘導体
ES2867749T3 (es) Conectores y su aplicación con respecto a los CAF
CN106459055A (zh) 双功能细胞毒类药剂
TWI712605B (zh) 含有ｃｔｉ藥效基團之雙功能性細胞毒性劑
JP2023528412A (ja) 抗ｂｃｍａ抗体－薬物コンジュゲート及び使用方法
US20260042773A1 (en) Novel camptothecin analogs and immunoconjugates thereof
JP2025518554A (ja) リガンド薬物複合体及びその使用
CN118829645A (zh) 新型澳瑞他汀类似物及其免疫偶联物
WO2025149667A1 (en) Antibody drug conjugates and uses thereof
IL312533A (en) Novel auristatin analogs and immunoconjugates thereof
EP4471005A1 (en) Conjugate and use thereof
CN118541378A (zh) 新型澳瑞他汀类似物及其免疫偶联物
HK40117241A (zh) 新型澳瑞他汀类似物及其免疫偶联物
RU2844846C2 (ru) Производные камптотецина
CA3137125C (en) Camptothecin derivatives
HK40115429A (zh) 新型澳瑞他汀类似物及其免疫偶联物
HK40104845A (en) Camptothecin derivatives
HK1233252A1 (en) Bifunctional cytotoxic agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40117241

Country of ref document: HK